Evidence map›Paper›PMID 42096231›Full record

ArticleJAMA oncology2026

Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer.

Michael S Leapman, John Rothen, Jessica B Long, Isaac E Kim, Aaron P Mitchell, James B Yu, Michaela A Dinan, Cary P Gross, Xiaomei Ma

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Error in Byline.JAMA oncology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Michael S LeapmanDepartment of Urology, Yale School of Medicine, New Haven, Connecticut.
John RothenCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale School of Medicine, New Haven, Connecticut.
Jessica B LongCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale School of Medicine, New Haven, Connecticut.
Isaac E KimDepartment of Urology, Stanford School of Medicine, Stanford, California.
Aaron P MitchellDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
James B YuDepartment of Radiation Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
Michaela A DinanCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale School of Medicine, New Haven, Connecticut.
Cary P GrossCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale School of Medicine, New Haven, Connecticut.
Xiaomei MaCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale School of Medicine, New Haven, Connecticut.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imagingR01CA281959 · NCI · YALE UNIVERSITY · PI Michael Stuart Leapman · 2023 to 2026
$2.6M
NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA281959
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42096231
PMCPMC13154023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.